375 related articles for article (PubMed ID: 19040592)
1. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
2. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Weber MA; Bakris GL; Dahlöf B; Pitt B; Velazquez E; Gupte J; Lefkowitz M; Hester A; Shi V; Weir M; Kjeldsen S; Massie B; Nesbitt S; Ofili E; Jamerson K
Blood Press; 2007; 16(1):13-9. PubMed ID: 17453747
[TBL] [Abstract][Full Text] [Related]
3. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
4. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
5. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
Chrysant SG; Bakris GL
Am J Hypertens; 2004 Jul; 17(7):590-6. PubMed ID: 15233978
[TBL] [Abstract][Full Text] [Related]
6. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
[TBL] [Abstract][Full Text] [Related]
8. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
[TBL] [Abstract][Full Text] [Related]
9. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
10. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
[TBL] [Abstract][Full Text] [Related]
11. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
Kjeldsen SE; Jamerson KA; Bakris GL; Pitt B; Dahlöf B; Velazquez EJ; Gupte J; Staikos L; Hua TA; Shi V; Hester A; Tuomilehto J; Ostergren J; Ibsen H; Weber M;
Blood Press; 2008; 17(1):7-17. PubMed ID: 18568687
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Bakris GL; Toto RD; McCullough PA
J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
[TBL] [Abstract][Full Text] [Related]
13. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
[TBL] [Abstract][Full Text] [Related]
14. An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension.
Ueng KC; Lin LC; Voon WC; Lin MC; Liu YB; Su HM; Chang PY; Lin TH; Chen WL; Wu CC; Lai WT; Lin CS
Blood Press Suppl; 2008 Jun; 1():24-31. PubMed ID: 18705532
[TBL] [Abstract][Full Text] [Related]
15. [The ACCOMPLISH trial: are results really unexpected?].
Waeber B; Feihl F
Rev Med Suisse; 2009 Jan; 5(185):25-8. PubMed ID: 19216321
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
Jamerson KA; Bakris GL; Wun CC; Dahlöf B; Lefkowitz M; Manfreda S; Pitt B; Velazquez EJ; Weber MA
Am J Hypertens; 2004 Sep; 17(9):793-801. PubMed ID: 15363822
[TBL] [Abstract][Full Text] [Related]
17. Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension trial.
White WB; Cleveland JM; Rolleri RL;
J Hum Hypertens; 2008 Aug; 22(8):559-68. PubMed ID: 18463672
[TBL] [Abstract][Full Text] [Related]
18. Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Davis BR; Whelton PK;
N Engl J Med; 2009 Mar; 360(11):1148-9; author reply 1149-50. PubMed ID: 19283889
[No Abstract] [Full Text] [Related]
19. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
Fogari R; Malamani GD; Zoppi A; Mugellini A; Rinaldi A; Vanasia A; Preti P
J Hum Hypertens; 2003 Mar; 17(3):207-12. PubMed ID: 12624612
[TBL] [Abstract][Full Text] [Related]
20. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
Aksnes TA; Kjeldsen SE; Rostrup M; Störset O; Hua TA; Julius S
J Hum Hypertens; 2008 Aug; 22(8):520-7. PubMed ID: 18509347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
